tiprankstipranks
InflaRx NV (IFRX)
NASDAQ:IFRX
US Market
IFRX
InflaRx
RESEARCH TOOLSreports

InflaRx (IFRX) Stock News & Sentiment

854 Followers
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
Premium
Company Announcements
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
6d ago
6K
IFRX
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
Premium
Company Announcements
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
21d ago
6K
IFRX
IFRX Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
IFRX Earnings this Week: How Will it Perform?
23d ago
IFRX
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
Premium
Company Announcements
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027
3M ago
6K
IFRX
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
Premium
Ratings
InflaRx: Cost Discipline and Strategic Refocus on Izicopan Underpin Buy Rating
3M ago
IFRX
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
Premium
Company Announcements
InflaRx Reveals Phase 3 Post‑Hoc Efficacy Signals for Vilobelimab in Pyoderma Gangrenosum After Trial Halt
3M ago
6K
IFRX
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
Premium
Ratings
Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
5M ago
IFRX
More IFRX News >

IFRX News on the Web

InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
TipRanks News
Neutral
Guggenheim Reaffirms Their Buy Rating on InflaRx (IFRX)
TipRanks News
Neutral
InflaRx presents vilobelimab data
TipRanks News
Bullish
InflaRx price target lowered to $14 from $22 at Guggenheim
TipRanks News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Sarepta Therapeutics (SRPT)
TipRanks News
Bullish
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
Zacks
Bearish
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
TipRanks News
Bearish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IFRX’s Media Buzz Sentiment?
Currently, no data Available
What is IFRX’s weekly average amount of articles?
Currently, no data Available
What is IFRX’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
NBIXNeurocrine
AORTArtivion
HUMHumana
ORGOOrganogenesis Holdings
UNHUnitedHealth Group Incorporated Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
Showing the stocks with the most bullish news sentiment over the past week